Vicept Therapeutics has reported positive results from a Phase II clinical trial evaluating V-101 cream, a topical cream for the treatment of facial redness known as Type I Rosacea (ETR).
The results showed a statistically significant improvement in the primary endpoint, which was defined as a reduction in facial erythema over an eight-hour period in patients with ETR, compared to placebo
Go deeper with GlobalData
In addition, V-101 demonstrated a safety profile similar to the placebo cream, without any evidence of “rebound” or tachyphylaxis.
The prospectively randomised, multi-centred, double-blinded and placebo-controlled trial was designed to assess the dose-response relationship of four concentrations of V-101 cream versus.
A total of 183 patients with moderate to severe erythema were enrolled at seven investigational centres across the US.
Patients were divided among five groups and self-administered one of four concentrations of V-101 cream or placebo cream once daily for 28 days.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
